Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer’s disease: a modelling study

Key Points

• Patients treated with lecanemab experience delayed progression to moderate and severe Alzheimer's disease, enhancing quality of life.
• The modelling indicates that lecanemab leads to additional life-years and decreases time spent in institutional care across various patient scenarios.
• Health outcomes were estimated using advanced modelling techniques, focusing on the effects of early treatment initiation.
• Further validation may support broader use of lecanemab in clinical practice to benefit patients with early Alzheimer's disease.

Abstract